Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with classic Hodgkin lymphoma (confirmed by tissue testing) whose cancer has come back or stopped responding to chemotherapy that included a drug type called anthracycline, and who are considered suitable candidates for high-dose chemotherapy followed by a stem cell transplant using their own cells
• People aged 18 or older
• People who are generally well enough to carry out normal daily activities with little to no limitation (as assessed by their doctor using a standard scale)
• People whose cancer can be measured or detected on scans or physical examination, according to standard 2014 guidelines for lymphoma
• People whose life expectancy is greater than 90 days
• People whose blood test results meet specific minimum levels for white blood cells, platelets, haemoglobin, liver function, and kidney function (confirm with trial site for exact values)
• People who are able to complete quality of life questionnaires in either English or French
• People who are willing to sign a consent form before joining the trial
• People who are able to attend all required treatment appointments and follow-up visits
• People who are able to start treatment within 2 working days of being enrolled in the trial
• People of childbearing potential who have agreed to use a highly effective form of contraception during the trial and for approximately 6 months after treatment ends
• People who have tumour tissue samples available from their original diagnosis biopsy, and from their relapsed or non-responding disease if available, and whose treating centre has agreed to release those samples for research purposes

Who may not be able to join:

• People who have already received salvage (rescue) treatment for their relapsed or non-responding lymphoma
• People with a history of nerve damage in the hands or feet (peripheral neuropathy) or significant shortness of breath, at a moderate level or worse
• People with a history of another cancer, except for certain cancers that have been fully treated and resolved — such as some non-melanoma skin cancers, early-stage cervical or breast cancer, localised prostate cancer, or other solid tumours with no sign of return for more than 3 years
• People with a history of active cancer that has spread to the brain or central nervous system
• People with a diagnosis of a weakened immune system, or who have been taking steroid medications above a low dose, or any other immune-suppressing treatment, within the 7 days before starting trial treatment
• People with an autoimmune disease (where the immune system attacks the body) that has needed treatment in the past 3 years, or people who have previously had a transplant using another person's donated cells or tissue — note that routine hormone or gland replacement therapies are not considered immune-suppressing treatment for this purpose
• People with a known history of HIV, active hepatitis C, or active hepatitis B infection, or any uncontrolled serious infection currently requiring intravenous antibiotics — though some people with past hepatitis B or C infection may still be eligible (confirm with trial site)
• People with significant heart conditions such as uncontrolled irregular heartbeat, heart failure, chest pain (angina), or a heart attack within the past 6 months, or who have been classified as having moderate or severe heart disease by standard medical criteria
• People with a history of stroke or transient ischaemic attack (a brief, stroke-like episode)
• People with a history of a serious brain condition called progressive multifocal leukoencephalopathy (PML)
• People with any serious illness, including mental health conditions, that the treating doctor believes would make it unsafe to receive the trial treatment or complete follow-up
• People with any other serious or life-threatening illness or organ problems that the treating doctor believes could put the person at risk — for example, uncontrolled infections or significant heart problems
• People who have received a live vaccine within 4 weeks before joining the trial
• People who are pregnant or breastfeeding, or people of childbearing potential who are not willing to use an adequate method of contraception during the trial and for 6 months after the last dose of treatment
• People who have previously had a serious (grade 3 or above) reaction during an infusion of any of the study drugs or their ingredients
• People who have a history of lung inflammation (pneumonitis) not caused by infection that required steroid treatment, or who currently have pneumonitis
• People who have received a transplant using another person's donated tissue or solid organ
• People who have received another experimental drug or cancer treatment within 4 weeks before joining the trial
• People who have received radiation therapy within 2 weeks before starting the trial, or who have not yet fully recovered from side effects of radiation — a shorter gap of one week may be allowed for limited palliative radiation in some cases (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.